American Health Packaging Recalls Glipizide Tablets Due to Dissolution Failure
American Health Packaging recalls Glipizide Extended-Release Tablets, 2.5 mg due to failed dissolution specifications. Check your lot number and expiration date.
Use caution until it’s fixed
Failed Dissolution Specifications: results were above specification.
Contact the company
What happened, in plain English
American Health Packaging is recalling Glipizide Extended-Release Tablets, 2.5 mg because the medication failed to meet dissolution specifications. The test results showed that the drug was released at a rate above the required specification. This recall affects 2,266 cartons distributed nationwide within the USA. Read more at govinfonow.com/recall/35851-american-health-packaging-recalls-glipizide-tablets-due-to-dissolution-failure.
Source Summary by GovInfoNow · govinfonow.com/recall/35851-american-health-packaging-recalls-glipizide-tablets-due-to-dissolution-failure · Updated October 10, 2026 · FDA enforcement record: FDA #D-0020-2022
Cite this page
“American Health Packaging Recalls Glipizide Tablets Due to Dissolution Failure.” GovInfoNow, updated October 10, 2026. https://govinfonow.com/recall/35851-american-health-packaging-recalls-glipizide-tablets-due-to-dissolution-failure. Based on FDA recall #D-0020-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0020-2022%22&limit=1).
Why it’s dangerous
The tablets failed dissolution specifications, meaning the drug was released at a rate above specification. This could potentially lead to inconsistent dosing, where too much or too little of the active ingredient is absorbed by the body compared to what is expected from a properly dissolving tablet.
Who’s affected
Patients prescribed Glipizide Extended-Release Tablets by American Health Packaging who purchased the specific lot with an expiration date of 03/31/2022. Individuals managing diabetes or blood sugar levels may be affected if the medication does not release as intended.
How to tell if you have this one
Check if you have Glipizide Extended-Release Tablets, 2.5 mg, manufactured by Patheon Pharmaceuticals Inc. and distributed by Actavis Pharma, Inc. Look for Carton NDC# 68084-295-21 (Individual Dose NDC: 68084-295-11), Lot # 194141, with an expiration date of 03/31/2022.
- Brand
American Health Packaging- Category
Drug
What to do — step by step
Check Your Medication
Verify if your Glipizide Extended-Release Tablets match the recalled lot number 194141 and expiration date 03/31/2022.
Consult Your Pharmacist
Contact your pharmacist or healthcare provider to discuss how to handle the recalled medication, as no specific remedy is stated in the record.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide within the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 21 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Other American Health Packaging recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0020-2022 (September 17, 2021) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0020-2022 to see it in context.
- Plain-language summary written by qwen3.6:35b-a3b on October 10, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.